通过皮肤进行冠状动脉干预治疗稳定性心痛 (ORBITA):双盲随机对照试验
Rasha Al-Lamee1, David Thompson1, Hakim-Moulay Dehbi2
1Imperial College London, London, UK; Imperial College Healthcare NHS Trust, London, UK.
Lancet (London, England)
|November 7, 2017
概括
穿皮冠状动脉干预 (PCI) 与安慰剂相比,在稳定的心脏病患者中没有显著改善运动时间. 这一盲目的试验表明PCI
科学领域:
- 心脏病学
- 干预心脏病学
- 临床试验
背景情况:
- 皮肤冠状动脉干预 (PCI) 常用于缓解稳定性心痛的症状.
- 然而,从盲目的安慰剂对照试验中缺乏强有力的证据证明其在缓解心痛方面的有效性.
研究的目的:
- 评估PCI与安慰剂疗法在患有稳定性心痛和严重冠状动脉狭窄症的患者中的疗效.
- 在盲目的随机环境中评估PCI对运动能力和症状缓解的影响.
主要方法:
- 这项ORBITA试验是一项盲目的多中心随机对照试验.
- 患有严重单血管狭窄症的患者接受了优化药物治疗,然后随机分配到PCI或安慰剂程序.
- 主要终点是通过心肺运动测试评估的运动时间增加的差异.
主要成果:
- 在PCI组和安慰剂组之间没有观察到运动时间增加的显著差异 (16. 6秒,95% CI- 8. 9至42. 0, p=0. 200).
- 这项研究招募了200名患者,其中105人被随机分为PCI和95人接受安慰剂治疗.
- 没有死亡;严重的不良事件在不同组之间是可比的,而安慰剂组的一些并发症需要PCI.
结论:
- 与安慰剂相比,在经过药物治疗的心脏病和严重冠状动脉狭窄症患者中,PCI 在运动时间方面没有显著的额外益处.
- 这项研究强调了安慰剂对照试验在评估侵袭性心脏手术的有效性方面的重要性.
- 这些发现表明,PCI在该群体中的症状益处可能主要归因于程序效应,而不是直接的损伤再血管化.
相关概念视频
01:26Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
01:27Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
01:30Acute Coronary Syndrome I: Introduction
2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
01:30Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
01:28Acute Coronary Syndrome IV: Interprofessional Care
522
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
01:26Angina IV: Management
493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493